Novartis cites momentum in 3 percent profit rise - 13 WTHR Indianapolis

Novartis cites momentum in 3 percent profit rise

Posted: Updated:
  • NationalMore>>

  • GOP voters in Georgia decide Senate nominee

    GOP voters in Georgia decide Senate nominee

    Tuesday, July 22 2014 9:20 PM EDT2014-07-23 01:20:59 GMT
    After a bruising nine-week runoff campaign, Georgia Republicans will finally have their Senate nominee who will compete against Democrat Michelle Nunn for a seat the GOP can ill afford to lose as the party looks to...More >>
    Early returns Tuesday suggest a long night of vote counting in a tight race for Georgia's Republican Senate nomination between U.S. Rep. Jack Kingston and businessman David Perdue.More >>
  • In international flight, volatile conflicts abound

    In international flight, volatile conflicts abound

    Tuesday, July 22 2014 9:11 PM EDT2014-07-23 01:11:21 GMT
    In Libya, militias armed with shoulder-launched missiles are battling for control of the country's main airport. In Africa, the entire Sahel region is awash with weapons that include portable air defense...More >>
    In Libya, militias armed with shoulder-launched missiles are battling for control of the country's main airport. In Africa, the entire Sahel region is awash with weapons that include portable air defense systems...More >>
  • Crews make gains on massive Washington wildfire

    Crews make gains on massive Washington wildfire

    Tuesday, July 22 2014 9:11 PM EDT2014-07-23 01:11:14 GMT
    Firefighters and local authorities are heartened by weather forecasts that call for continued cooler temperatures and higher humidity as they battle a destructive wildfire that has charred hundreds of square miles...More >>
    Firefighters were making progress Tuesday in their efforts to get the largest wildfire in Washington state's history under control, with wetter weather bringing some relief but also raising concerns about flash flooding.More >>
By JOHN HEILPRIN
Associated Press

GENEVA (AP) - Swiss pharmaceutical company Novartis AG posted a 3 percent rise in second-quarter profits Thursday, reflecting what it described as solid growth and an increased focus on core products.

Profits during the April-June quarter rose to $3.28 billion, up from $3.18 billion in the same quarter of 2013, helped by "strong innovation momentum" and rising sales in some of its household brands, the Basel-based company reported.

Earlier this year, the company launched a major overhaul of its business with a series of multibillion-dollar deals with Britain's GlaxoSmithKline PLC and the U.S.'s Eli Lilly & Co., a reflection of the restructuring that's occurring in the fast-changing industry.

Novartis confirmed its outlook for 2014 is for mid-to-high single-digit sales growth, partly due to its confidence from progress and approvals for cancer and heart drugs that are in development.

CEO Joseph Jimenez told reporters the company delivered a solid quarter and is benefiting from "a sweeping transformation" of its commercial portfolio.

Novartis said Thursday its deal to buy GSK's cancer-drug business for $14.5 billion, plus up to $1.5 billion more if certain milestones are met, is now expected to close in the first half of 2015. The Swiss company has agreed to sell most of its vaccines business to GSK for $7.1 billion, plus royalties, giving GSK better market position with Bexsero, a meningitis B vaccine. The two firms are also creating a new consumer health care business.

Separately, Novartis is selling its animal health division to Eli Lilly for about $5.4 billion, in a deal it said Thursday is now expected to close in the first quarter of 2015. The Indianapolis-based Lilly has been hit hard by patent expirations and has staked its recovery in part on new drugs it develops and its animal health business.

Copyright 2014 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Powered by WorldNow